...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Critical Care Medicine >Off-label Drug Prescription Pattern and Related Adverse Drug Reactions in the Medical Intensive Care Unit
【24h】

Off-label Drug Prescription Pattern and Related Adverse Drug Reactions in the Medical Intensive Care Unit

机译：医学密集护理单位的标签药物处方模式及相关不良药物反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The utilization of prescription drugs as off-label is common. While this practice can be beneficial to some patients, it can raise a safety concern when scientific evidence is lacking; hence, this study was conducted to evaluate the off-label drug consumption and its adverse drug reactions (ADRs) in the medical intensive care unit (ICU). Materials and methods: In the prospective cohort study conducted for a duration of 6 months, data pertaining to ICU patients’ (age ≥18 years) demography, diagnosis, treatment, and laboratory investigation were collected to assess for off-label use as well as the strength of evidence and the occurrence of ADRs by using MICROMEDEX 2017 version (Healthcare Series Thomson Reuter, Greenwood, CO). Results: Of total 3574 drugs prescribed, 1453 (41%) were off-label indications and 65 (1.81%) were off-label dose. On the evaluation of off-label indication use, 1279 (88%) were evidence-based and 174 (12%) were low/no evidence-based medications (EBMs); 59 (91%) were evidence-based and 6 (9%) were low/no EBMs for off-label dose. Most commonly prescribed evidence-based off-label drug belonged to the gastrointestinal class while low/no evidence drugs were mostly of anti-infective class. A total of 383 ADRs were identified and 139 (36.2%) were implicated due to off-label medications, of which ADRs with evidence off-label medications (87.8%) were higher than low/no evidence off-label medication (12.2%) (P 0.001).
机译：介绍：使用处方药作为偏标是常见的。虽然这种做法对某些患者有益，但当科学证据缺乏时，它可以提高安全问题;因此，该研究进行了评估医学密集护理单位（ICU）中的标签药物消耗及其不良药物反应（ADRS）。材料和方法：在预期队列研究中进行了6个月的持续时间，收集了与ICU患者（年龄≥18岁）的数据，收集了人口，诊断，治疗和实验室调查，以评估了非标签使用以及使用Micromedex 2017版本的证据和ADRS的实力（医疗系列Thomson Reuter，Greenwood，Co）。结果：总共3574种规定的药物，1453（41％）为偏非标签指示，65（1.81％）偏离标签剂量。在评估Off-Label指示使用中，1279（88％）是基于证据的，174名（12％）是低/无循证药物（EBMS）; 59（91％）是基于证据的，6（9％）低/无EBMS用于非标签剂量。最常见的基于证据的基于证据的无标签药物属于胃肠级，而低/没有证据药主要是抗病阶级。鉴定了总共383个ADR，并且由于非标签药物，139名（36.2％）涉及，其中ADR有证据表明药物（87.8％）的含量高于低/无证据表明药物（12.2％） （P <0.001）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号